Showing 1411-1420 of 1685 results for "".
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- J&J Looking to Enroll 60,000 Participants in Coronavirus Vaccine Trialhttps://modernod.com/news/jj-looking-to-enroll-60000-participants-in-coronavirus-vaccine-trial/2478185/A phase 3 trial Johnson & Johnson is planning to get under way in September to test its coronavirus vaccine candidate Ad26.COV2.S is looking to recruit up to 60,000 participants globally, the company confirmed Thursday. The targeted enrollment, first reported on the ClinicalTrials.gov databas
- J&J Vaccine Protects Monkeys From Covid With Single Shothttps://modernod.com/news/jj-vaccine-protects-monkeys-from-covid-with-single-shot/2478099/Johnson & Johnson’s experimental coronavirus vaccine protected a group of macaques with a single shot in an early study, prompting the U.S. drugmaker to start trials in humans this month, according to a Bloomberg
- OneSight Seeks Volunteer ODs for Charitable Clinicshttps://modernod.com/news/onesight-seeks-volunteer-ods-for-charitable-clinics/2479133/OneSight, which provides vision care access to more than 50 million people globally through charitable vision clinics and permanent vision centers, is in need of optical professionals to volunteer their skills to help reach the 1.1 billion people worldwide who lack access to eye exams and glasses
- Perry J. Sternberg Joins Sydnexis as Chief Executive Officerhttps://modernod.com/news/perry-j-sternberg-joins-sydnexis-as-chief-executive-officer/2482358/Sydnexis has announced the appointment of Perry J. Sternberg as Chief Executive Officer and a member of the Board of Directors. Mr. Sternberg is a pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Immediately prior to joining Sydnexis,
- Iveric Bio Receives Permanent J-code for GA Treatment Izervayhttps://modernod.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/Iveric Bio, a subsidiary of Astellas, announced that CMS has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macula
- Edward J. Holland, MD, to Join Alcon as Member of the Research and Development Teamhttps://modernod.com/news/edward-j-holland-md-to-join-alcon-as-member-of-the-research-and-development-team/2481000/Alcon announced that Edward J. Holland, MD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Holland is a thought leader in ophthalmology, specializing in the field of cornea and the ocular surface. He will serve as an enterprise Senior Scientifi
- TearClear Appoints Robert J. Dempsey Chief Executive Officerhttps://modernod.com/news/tearclear-appoints-robert-j-dempsey-chief-executive-officer/2477596/TearClear announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface, that are preserved safely prior to dosing, according to a company news release. <
- EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for Yutiq Now in Effecthttps://modernod.com/news/eyepoint-pharmaceuticals-announces-permanent-and-specific-j-code-for-yutiq-now-in-effect/2476934/EyePoint Pharmaceuticals announced that the company’s permanent and specific J-Code for Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye is now in effect. The code, J7314, was issued by the
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the